Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 1;2(2):pky018.
doi: 10.1093/jncics/pky018. eCollection 2018 Apr.

Exclusion of Male Patients in Breast Cancer Clinical Trials

Affiliations

Exclusion of Male Patients in Breast Cancer Clinical Trials

Narjust Duma et al. JNCI Cancer Spectr. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consort diagram depicting the criteria used to identify trials used in the analysis.

References

    1. Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2018. CA Cancer J Clin. 2018;681:7–30. - PubMed
    1. Cardoso F, Bartlett JMS, Slaets L et al. , . Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;292:405–417. - PMC - PubMed
    1. Strauss LC, O'Shaughnessy J, Jackson J et al. , . Three parallel randomized phase II trials of dasatinib plus hormone therapy (HT) in advanced ER+ breast cancer (ER+ ABC). J Clin Oncol. 2010;28(15_suppl):TPS133–TPS133.
    1. Reinisch M, Seiler S, Hauzenberger T et al. , . Abstract PD7-10: Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. Cancer Res. 2018;78(4 Supplement):PD7-10-PD7-10.
    1. Giordano SH, Hortobagyi GN.. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol. 2006;2421:e42–e43. - PubMed

LinkOut - more resources